GPATCH1

Across TCGA pan-cancer cohorts, GPATCH1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GPATCH1 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GPATCH1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GPATCH1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where GPATCH1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.592	0.839	<.001	52	view →
PDAC	OS	Tertile	IV	0.836	0.455	.024	8	view →
CCRCC	OS	Quartile	II,III,IV	0.574	0.958	.006	6	view →
GBM	OS	Tertile	All	0.644	0.447	.023	5	view →
LUAD	DFS	Median	III,IV	0.893	0.618	.039	3	view →
LSCC	DFS	Quartile	II,III,IV	0.252	1.000	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GPATCH1–HNSC (OS)

Open the HNSC breakdown →